telaprevir (incivek) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Telaprevir (marketed under the brand names Incivek and Incivo) is a direct-acting antiviralagent against the hepatitis C virus (HCV). It is a hepatitis C virus NS3/4A protease inhibitor indicated for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null responders, partial responders, and relapsers in combination with peginterferon alfa and ribavirin. Telaprevir is not used as a monotherapy. It is necessary for the proteolytic cleavage of the HCV encoded polyprotein into mature forms of the NS4A, NS4B, NS5A and NS5B proteins and essential for viral replication. It belongs to the chemical class of alpha-ketoamids and binds to NS3/4A in a covalent but reversible manner.   NCATS

Chemistry

  • SMILES: CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C3=NC=CN=C3)C4CCCCC4)C(C)(C)C)C(=O)C(=O)NC5CC5
  • InChIKey: BBAWEDCPNXPBQM-GDEBMMAJSA-N
  • Mol. Mass: 679.8493
  • ALogP: 2.45
  • ChEMBL Molecule:
    telaprevir  
More Chemistry

Pharmacology

Alternative names

(1s,3ar,6as)-(2s)-2-cyclohexyl-n-(pyrazinylcarbonyl)glycyl-3-methyl-l-valyl-n-((1s)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamide | incivek | incivo | mp-424 | telapravir | telaprevir | vrt-111950 | vx 950 | vx-950 | vx950 cpd

Organizations (43)

Research & Development (42)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (1)


 

Hepatitis C, Chronic (approved 2011)

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Acquired Immunodeficiency Syndrome (Phase 1)

Depression (Phase 2)

Drugs, Investigational (Phase 1)

Healthy Volunteers (Phase 1)

Hemophilia A (Phase 1)

Hepacivirus (Phase 3)

Hepatic Insufficiency (Phase 1)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

HIV (Phase 3)

HIV Infections (Phase 2)

Infections (Phase 3)

Kidney Diseases (Phase 1)

Liver Diseases (Phase 1)

Opioid-Related Disorders (Phase 1)

Thrombocytopenia (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 86
  • # of Trial Organizations: 42

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue